Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results

Παρόμοια τεκμήρια

• Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
  ανά: Morrow, Matthew P, κ.ά.
  Έκδοση: (2016)
• Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
  ανά: Bhuyan, Prakash K., κ.ά.
  Έκδοση: (2020)
• DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
  ανά: Humeau, Laurent, κ.ά.
  Έκδοση: (2014)
• Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
  ανά: Hollenberg, Rebecca K., κ.ά.
  Έκδοση: (2019)
• Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
  ανά: Vonderheide, Robert H, κ.ά.
  Έκδοση: (2021)